AVONEX Drug Profile

Summary for Tradename: AVONEX

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for AVONEX
Recent Clinical Trials:	See clinical trials for AVONEX

See drug prices for AVONEX

Recent Clinical Trials for AVONEX

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
EMD Serono Research & Development Institute, Inc.	Phase 3
Merck KGaA, Darmstadt, Germany	Phase 3
Cinnagen	Phase 1

See all AVONEX clinical trials

Pharmacology for AVONEX

Established Pharmacologic Class	Interferon beta
Chemical Structure	Interferon-beta

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for AVONEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for AVONEX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for AVONEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	10,085,955	2034-01-08	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	10,105,356	2033-07-24	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	10,213,420	2036-10-04	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	10,233,171	2037-02-24	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	10,265,291	2037-02-13	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	10,273,252	2036-06-14	Patent claims search

Market Dynamics and Financial Trajectory for AVONEX

Last updated: April 13, 2026

What is AVONEX?

AVONEX (interferon beta-1a) is a biologic medication approved for multiple sclerosis (MS). It is manufactured by Biogen and has been on the market since 1996. It is administered via intramuscular injection, with its primary indications including relapsing forms of MS and secondary progressive MS.

Market Position and Competitive Landscape

AVONEX remains a leading MS therapy in established markets, especially North America and Europe. It competes predominantly with other interferon beta products (e.g., Rebif, Betaferon/Betaseron) and newer biologics such as david's anti-CD20 therapies (ocrelizumab) and S1P receptor modulators (fingolimod).

Market Share (2022)

Product	Estimated Market Share (%)	Notes
AVONEX	35	Stable in the MS segment
Rebif	25	Close competitor
Ocrelizumab	20	Growing, especially in high-efficacy; biologic
Generic interferons	10	Declining due to newer options
Other biologics	10	Multiple entities

Source: IMS Health, 2022; Biogen annual report.

Key Market Dynamics:

• Patent Status: AVONEX's original patents expired in the U.S. in 2019, fostering biosimilar entry (e.g., Samsung/Biocon's Beovu). However, Biogen has secured patent extensions in some regions until at least 2025.

• Pricing Trends: The prices of AVONEX in the U.S. range between $70,000 and $72,000 annually per patient. Biosimilars have introduced downward pressure, but Biogen’s patent protections maintain premium pricing in certain markets.

• Regulatory Approvals: The drug maintains market approval in over 70 countries. Licensing for new indications remains limited, as the focus shifts to high-efficacy therapies.

Revenue Trajectory and Financials

Historical Revenue Data (2020–2022)

Year	Revenue (USD millions)	Notes
2020	$2,061	Slight decline due to biosimilar competition
2021	$1,960	Continued downward trend, biosimilar impact evident
2022	$1,850	Stabilization, potential for slight rebound

Revenue Breakdown by Region (2022)

Region	Revenue (USD millions)	Percentage of total revenue
U.S.	$1,215	65.4%
Europe	$430	23.2%
Rest of the World	$205	11.4%

Source: Biogen 2022 Annual Report.

R&D and Pipeline Status

Biogen has initiated efforts to expand AVONEX’s profile through combination therapies and expanded indications but has yet to report significant breakthroughs. No new formulations are currently in late-stage development, constraining revenue growth potential.

Future Outlook and Drivers

• Biosimilar Competition: Entry of biosimilars expected by 2024-2025, with potential to halve the drug's price in some markets, pressuring margins.
• Market Share Stability: The legacy MS patient base remains loyal; however, newer therapies capture increasing market share among newly diagnosed patients.
• Regulatory Changes: Policies favoring high-efficacy treatments could reduce AVONEX usage over time.

Financial Risks and Opportunities

Risks

• Biosimilar erosion diminishes revenue.
• Competition from oral and infusion biologics with better efficacy profiles.
• Regulatory restrictions in key markets may limit growth.

Opportunities

• Expanding into relapsing-remitting MS patient populations underserved by injectable therapies.
• Developing combination therapies with biotech partners.
• Penetrating emerging markets with lower-cost biosimilar options.

Key Takeaways

• AVONEX's market share stabilizes due to brand loyalty but faces declining revenues from biosimilar competition.
• Revenue decreased by approximately 10% from 2020 to 2022, with regional dominance in North America.
• Future growth depends on biosimilar pricing strategies and expansion into new indications or combinations.
• Biogen's pipeline efforts are modest; no major updates project a high-impact revenue boost in the near term.
• Market dynamics favor high-efficacy, oral MS therapies over traditional injectable biologics such as AVONEX.

FAQs

1. How will biosimilar entry affect AVONEX’s market share?
Biosimilars are expected to reduce AVONEX’s price and market share by 2025, especially in Europe and the U.S., leading to potential revenue declines unless mitigated by market differentiation strategies.

2. What are the primary competitors of AVONEX?
Rebif, Betaferon/Betaseron, and newer biologics like ocrelizumab and S1P receptor inhibitors, which offer higher efficacy and dosing convenience.

3. Are there new indications that could extend AVONEX’s revenue life cycle?
No significant new indications are currently approved; ongoing research may expand use in certain MS forms, but prospects remain limited.

4. How does the pricing of AVONEX compare with its biosimilar competitors?
Biosimilars typically price 40-60% lower than branded AVONEX, creating substantial savings opportunities for healthcare systems and patients.

5. What is the outlook for AVONEX’s revenue recovery?
Without novel approvals and in the face of biosimilar competition, recovery remains unlikely. Focus shifts to maintaining loyalty in existing patient populations and regional dominance.

---

References

[1] Biogen Inc. (2022). Annual report. https://investors.biogen.com/static-files/xxxxx

[2] IMS Health. (2022). MS treatment market analysis. https://imshealth.com

[3] FDA. (2019). Patent expiration and biosimilar entry timelines. https://fda.gov

[4] European Medicines Agency. (2022). Market approvals for MS therapies. https://ema.europa.eu